Skip to Main Content

RECALL: Emerade epinephrine auto-injectors

Posted May 9th, 2023 in Awareness, Health

Bausch Health, Canada Inc. recalls all lots of Emerade epinephrine auto-injectors (0.3 mg and 0.5 mg strengths) due to possible device failure

recalled epinephrine recalled emerade epinephrine

Bausch Health, Canada Inc. is recalling all lots of Emerade epinephrine auto-injectors (0.3 mg and 0.5 mg) after testing by the company identified the potential risk that the auto-injector may fail to activate, or it may activate prematurely if dropped.

The affected lots of Emerade were distributed in Canada between April 2022 and May 2023.

Emerade auto-injectors are used to deliver an emergency treatment of epinephrine to patients who are at risk or have a history of serious allergic reactions (anaphylaxis).

Failure of the auto-injector to activate may result in patients not receiving the required dose of epinephrine, leading to the worsening of symptoms of anaphylaxis which could be life-threatening.

Health Canada recognizes how important epinephrine auto-injectors are for people with life-threatening allergies. There are alternative epinephrine auto-injectors available in Canada. Ensuring Canadians can get the medicines they need is one of Health Canada’s top priorities. A shortage of alternative products is not expected, but the Department will continue to actively monitor the supply situation.

Contact Bausch Health, Canada Inc. by calling 1-800-361-4261, or emailing , if you have questions about the recall.

This message could be about your business. Ask us.

  • Thanks Debi. I follow Connecting Niagara on Twitter and Facebook as well. It's nice to have a site that promotes local events and organizations. We appreciate the support and promotion of our event.
    ~ Dan M.


Powered by PRowl Communications

9053215097 Contact